ATTUNE Revision Knee System for Total Knee Replacement
Trial Summary
The trial information does not specify if you need to stop taking your current medications. However, if you are taking prescription medications for a muscular disorder that limits mobility, you may not be eligible to participate.
Research shows that the ATTUNE Knee System, a newer design, may offer better knee movement and tracking compared to older systems like the PFC Sigma. Studies also suggest that it could improve patient satisfaction and function after knee replacement surgery.
12345The ATTUNE Revision Knee System is unique because it is a second-generation modular system designed to address the challenges of revision knee surgery, offering improved stability, function, and implant longevity compared to standard options. It includes features like offset stems and various levels of constraint to better fit individual patient needs.
24678Eligibility Criteria
This trial is for men and women aged 22-80 who need a complex primary total knee replacement. Participants must be able to understand the study, follow procedures, and not be bedridden. Exclusions include pregnant or lactating women, those with prior knee replacements in the affected leg, inflammatory arthritis diagnoses, spine-related radiating pain, life expectancy under five years due to other medical conditions, recent participation in other clinical trials (last three months), substance abuse history (last five years), severe mobility-limiting muscular disorders like fibromyalgia.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo primary total knee arthroplasty using the ATTUNE Revision knee system
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 1, 2, and 5 years
Long-term follow-up
Participants continue to be monitored for long-term outcomes and survivorship of the knee system
Participant Groups
ATTUNE Revision Knee System is already approved in United States for the following indications:
- Severe pain and disability due to permanent structural damage resulting from rheumatoid arthritis, osteoarthritis, posttraumatic arthritis, collagen disorders, pseudogout, trauma or failed prior surgical intervention